Axsome Therapeutics (AXSM) Capital Expenditures (QoQ) (2015 - 2026)
Powered by 
Analysis
Axsome Therapeutics (AXSM) Capital Expenditures (QoQ) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Axsome Therapeutics | 10.75 Bn | 10.43 Bn | 204.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 271.90% |
| Mar 31, 2026 | 70.42% |
| Dec 31, 2025 | 22.41% |
| Sep 30, 2025 | 346.15% |
| Jun 30, 2025 | -96.15% |
| Mar 31, 2025 | 1,026.67% |
| Dec 31, 2024 | -66.67% |
| Sep 30, 2024 | 73.08% |
| Jun 30, 2024 | -46.94% |
| Mar 31, 2024 | 1,300.00% |
| Dec 31, 2023 | -98.11% |
| Sep 30, 2023 | 178.95% |
| Jun 30, 2023 | 87.32% |
| Mar 31, 2023 | -60.77% |
| Dec 31, 2022 | 174.24% |
| Sep 30, 2022 | -72.61% |
| Jun 30, 2022 | 12.62% |
| Mar 31, 2022 | 47,350.11% |
| Dec 31, 2021 | -99.83% |
| Sep 30, 2021 | 1,270.33% |